Researchers report on a targeted molecular therapy that dramatically reduces the initial development of non-alcoholic fatty liver disease (NAFLD) in laboratory mouse models of the disease. The study found increased levels of an enzyme called cdk4 in patients with NAFLD and in mouse models. Using two drugs that inhibit cdk4 in mouse models reduced development of hepatic steatosis -- the first stage of the disease.

Source: Study finds potential treatment for non-alcoholic fatty liver disease